BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2822926)

  • 1. Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity.
    Sircar I; Weishaar RE; Kobylarz D; Moos WH; Bristol JA
    J Med Chem; 1987 Nov; 30(11):1955-62. PubMed ID: 2822926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.
    Sircar I; Steffen RP; Bobowski G; Burke SE; Newton RS; Weishaar RE; Bristol JA; Evans DB
    J Med Chem; 1989 Feb; 32(2):342-50. PubMed ID: 2536438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotonic agents. 6. Synthesis and inotropic activity of 2,4-dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-3H-pyrazol-3-ones: ring-contracted analogues of imazodan (CI-914).
    Sircar I; Morrison GC; Burke SE; Skeean R; Weishaar RE
    J Med Chem; 1987 Oct; 30(10):1724-8. PubMed ID: 3656349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.
    Wynne DG; Poole-Wilson PA; Harding SE
    Br J Pharmacol; 1993 Aug; 109(4):1071-8. PubMed ID: 7691363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
    Sircar I; Duell BL; Bobowski G; Bristol JA; Evans DB
    J Med Chem; 1985 Oct; 28(10):1405-13. PubMed ID: 2864447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-(4-Guanidinobenzoyl)-2-imidazolones and related compounds: phosphodiesterase inhibitors and novel cardiotonics with combined histamine H2 receptor agonist and PDE III inhibitor activity.
    Glass D; Buschauer A; Tenor H; Bartel S; Will-Shahab L; Krause EG
    Arch Pharm (Weinheim); 1995 Oct; 328(10):709-19. PubMed ID: 8554460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotonic agents. 3. Synthesis and biological activity of novel 6-(substituted 1H-imidazol-4(5)-yl)-3(2H)-pyridazinones.
    Sircar I; Bobowski G; Bristol JA; Weishaar RE; Evans DB
    J Med Chem; 1986 Feb; 29(2):261-7. PubMed ID: 3950907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
    Weishaar RE; Quade MM; Schenden JA; Evans DB
    J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
    Ahn HS; Eardley D; Watkins R; Prioli N
    Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
    Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
    J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
    Price B; Pyne NJ; Houslay MD
    Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium.
    Bethke T; Meyer W; Schmitz W; Scholz H; Wenzlaff H; Armah BI; Brückner R; Raap A
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):847-55. PubMed ID: 7687707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.
    Reeves ML; Leigh BK; England PJ
    Biochem J; 1987 Jan; 241(2):535-41. PubMed ID: 3036066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase.
    Lampe JW; Chou YL; Hanna RG; Di Meo SV; Erhardt PW; Hagedorn AA; Ingebretsen WR; Cantor E
    J Med Chem; 1993 Apr; 36(8):1041-7. PubMed ID: 8386770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.
    Weishaar RE; Burrows SD; Kobylarz DC; Quade MM; Evans DB
    Biochem Pharmacol; 1986 Mar; 35(5):787-800. PubMed ID: 3006691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility.
    Weishaar RE; Kobylarz-Singer DC; Steffen RP; Kaplan HR
    Circ Res; 1987 Oct; 61(4):539-47. PubMed ID: 2820608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.
    Brunkhorst D; v der Leyen H; Meyer W; Nigbur R; Schmidt-Schumacher C; Scholz H
    Naunyn Schmiedebergs Arch Pharmacol; 1989 May; 339(5):575-83. PubMed ID: 2549430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of NSP-804 and NSP-805, novel cardiotonic agents with vasodilator properties.
    Mochizuki N; Uchida S; Miyata H
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):983-95. PubMed ID: 7687727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.
    Bristol JA; Sircar I; Moos WH; Evans DB; Weishaar RE
    J Med Chem; 1984 Sep; 27(9):1099-101. PubMed ID: 6471063
    [No Abstract]   [Full Text] [Related]  

  • 20. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
    Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
    Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.